Beryl Drugs Ltd Stock Price Today (NSE: BERLDRG)
Fundamental Score
Beryl Drugs Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Beryl Drugs Ltd share price today is ₹19.06, up +0.42% on NSE/BSE as of 15 April 2026. Beryl Drugs Ltd (BERLDRG) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹11.54 (Cr). The 52-week high for BERLDRG share price is ₹30.00 and the 52-week low is ₹15.92. At a P/E ratio of 50.15x, BERLDRG is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 6.30% and a debt-to-equity ratio of 0.45.
Beryl Drugs Ltd Share Price Chart — NSE/BSE Historical Performance
AI Research Briefing
Powered by Gemini · 2026-04-15
Overvalued micro-cap turnaround story with stagnant recent performance and illiquidity risk.
⚡ WHAT'S HAPPENING NOW (last 2-4 weeks): Beryl Drugs convened an EOGM on May 11, 2026, to approve the regularization of directors and a related party transaction. The stock price as of April 12, 2026, was ₹24.3. No share transfer activities occurred during the quarter ended March 31, 2026. 🧠 CORE STORY (THE REAL GAME): Beryl Drugs is a micro-cap domestic pharma play. The market is likely viewing it as a turnaround story, given the historical EPS growth, but recent lack of profit growth raises concerns. 🔥 WHAT IS DRIVING THE STOCK: 1. **Potential Turnaround:** 5Y Profit CAGR of 63.26% suggests a potential turnaround story. 2. **Domestic Focus:** Minimal direct impact expected from geopolitical events like the Iran-Israel conflict. 3. **EOGM Approval:** Upcoming EOGM on May 11, 2026, to approve related party transaction with Aminova Infusions P. Ltd. worth ₹5 crore for product distribution. ⚖️ BULL vs BEAR: Bull: Turnaround story with high EPS growth potential. Domestic focus shields it from global turmoil. Related party transaction could boost turnover. Bear: Micro-cap with illiquidity risk. Latest quarter YoY profit is flat, and sales are down 8.51%. Overvalued at P/E of 50.15x vs. industry P/E of 31.77x. Zero share transfer activity raises liquidity concerns. 💣 WHAT MARKET IS PRICING: The market is pricing in a continuation of the historical high EPS growth. If the upcoming quarters show continued stagnation, expect a correction. 🎯 BOTTOM LINE: Beryl Drugs is a high-risk, high-reward micro-cap play trading at a premium with questionable liquidity. Avoid until consistent profit growth resumes.
- EOGM on May 11, 2026, for related party transaction approval
- Stock upgraded to sell on technical improvements despite flat financials
- India Pharma 2026 concludes with a strong push for enhanced funding, infrastructure and speed to accelerate pharmaceutical innovation
- Significant order wins
- Consistent quarterly profit growth
- Successful integration of related party transaction
- Micro/SME cap: Illiquidity risk
- Overvalued: P/E 50.15x vs Industry P/E 31.77x
- Zero share transfer activity: Liquidity concerns
No FII/DII presence. Promoter holding stable at 26.38%.
India Pharma 2026 highlighting the need for enhanced funding and infrastructure could be a tailwind.
Yes: Free Cash Flow 5Y: ₹2.77 Cr
Monitor for consistent profit growth and successful related party transaction integration. A sustained turnaround is needed to justify the current valuation.
Primary Thesis Risk
Failure to achieve consistent profit growth will lead to valuation collapse.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Beryl Drugs Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Beryl Drugs Share Price: A Financial Stability Analysis
The pharmaceutical industry, known for its defensive characteristics, faces unique challenges in India, including price controls and evolving regulatory landscapes. This analysis provides a preliminary assessment of the financial stability of Beryl Drugs Ltd, focusing on its current valuation and profitability metrics. Currently, the Beryl Drugs share price stands at ₹21.06999969482422. This analysis is part of a comprehensive 80-parameter fundamental audit, meticulously verified by Sweta Mishra.
Beryl Drugs Ltd's Price-to-Earnings (PE) ratio is 50.15. This is a relatively high valuation compared to the broader market, suggesting investors have high growth expectations for the company. However, it's important to contextualize this within the pharmaceutical sector. Peer comparison is crucial here. For example, we can see how the market values
Mankind Pharma Ltd.The Return on Capital Employed (ROCE) for Beryl Drugs Ltd is 10.15%. ROCE measures how efficiently a company is generating profits from its capital. While positive, a ROCE of 10.15% is generally considered moderate. A higher ROCE would indicate a stronger ability to generate returns and potentially create a wider economic moat, protecting the company from competitors. Considering this, we can compare it with other peers like Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd. It helps highlight how Beryl Drugs compares in creating value.
Management quality plays a significant role in a pharmaceutical company's success. Firms like
Mankind Pharma Ltd are often recognized for their robust leadership teams and effective strategic execution. While this analysis does not delve into a qualitative assessment of Beryl Drugs Ltd.'s management, it is an important factor to consider when evaluating the long-term prospects of the company. Further research, including evaluating insider ownership and analyzing management commentary, would provide valuable insights. It is important to observe key metrics and not make any buy/sell recommendations based on any single factor.Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Beryl Drugs Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BERLDRG across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Excellent EPS Growth (63.26% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (63.26% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Below-Average Return on Equity (6.30%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Premium Valuation Risk (P/E: 50.15x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Revenue Contraction (-8.51%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Low Promoter Commitment (26.38%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Beryl Drugs Ltd Financial Statements
Comprehensive financial data for Beryl Drugs Ltd including income statement, balance sheet and cash flow
About BERLDRG (Beryl Drugs Ltd)
Beryl Drugs Ltd is a dynamic pharmaceutical entity rooted in the heart of India, dedicated to the development, production, and distribution of a diverse range of pharmaceutical sol...utions. Driven by a commitment to improving healthcare outcomes, the company meticulously crafts both branded and generic formulations, ensuring access to essential medicines for a wide spectrum of patients. Beyond traditional pills and tablets, Beryl Drugs specializes in sophisticated delivery systems including intravenous fluids and small volume injectables in both liquid and lyophilized forms. This comprehensive approach extends to specialized areas such as ophthalmic and otic solutions, alongside a dedicated line of veterinary products, solidifying its position as a versatile player in the pharmaceutical landscape. At the core of Beryl Drugs lies a robust infrastructure encompassing cutting-edge research and development capabilities. This investment in innovation fuels the creation of novel drug formulations and delivery methods, ensuring the company remains at the forefront of pharmaceutical advancements. Supplementing its in-house production, Beryl Drugs also provides contract manufacturing services, leveraging its state-of-the-art facilities and expertise to support other pharmaceutical companies. Stringent quality control measures permeate every stage of production, guaranteeing the safety and efficacy of all products bearing the Beryl Drugs name. Furthermore, the company actively pursues export opportunities, expanding its reach and contributing to global healthcare access. Established in 1993 and headquartered in the bustling city of Indore, Beryl Drugs Ltd has steadily grown to become a respected name in the Indian pharmaceutical industry. The company's success is built upon a foundation of ethical business practices, a skilled workforce, and a steadfast dedication to meeting the evolving needs of the healthcare sector. Through continuous investment in research, technology, and talent, Beryl Drugs remains poised to further its mission of providing high-quality, affordable medicines to improve the lives of people and animals, both domestically and internationally. Its long-standing presence in the market reflects its reliability and commitment to sustained growth and innovation.
Company Details
Key Leadership
BERLDRG Share Price: Frequently Asked Questions
What is the current share price of Beryl Drugs Ltd (BERLDRG)?
As of 15 Apr 2026, 11:00 am IST, Beryl Drugs Ltd share price is ₹19.06. The BERLDRG stock has a market capitalisation of ₹11.54 (Cr) on NSE/BSE.
Is BERLDRG share price Overvalued or Undervalued?
BERLDRG share price is currently trading at a P/E ratio of 50.15x, compared to the industry average of 31.77x. Based on this relative valuation, the Beryl Drugs Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of BERLDRG share price?
The 52-week high of BERLDRG share price is ₹30.00 and the 52-week low is ₹15.92. These values are updated daily from NSE/BSE price data.
What factors affect the Beryl Drugs Ltd share price?
Key factors influencing BERLDRG share price include quarterly earnings growth (Sales Growth: -8.51%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Beryl Drugs Ltd a good stock for long-term investment?
Beryl Drugs Ltd shows a 5-year Profit Growth of 63.26% and an ROE of 6.30%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.45 before investing in BERLDRG shares.
How does Beryl Drugs Ltd compare with its industry peers?
Beryl Drugs Ltd competes with major peers in the Pharmaceuticals. Investors should compare BERLDRG share price P/E of 50.15x and ROE of 6.30% against the industry averages to determine competitive standing.
What is the P/E ratio of BERLDRG and what does it mean?
BERLDRG share price has a P/E ratio of 50.15x compared to the industry average of 31.77x. Investors pay ₹50 for every ₹1 of annual earnings.
How is BERLDRG performing according to Bull Run's analysis?
BERLDRG has a Bull Run fundamental score of 27.4/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does BERLDRG belong to?
BERLDRG operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Beryl Drugs Ltd share price.
What is Return on Equity (ROE) and why is it important for BERLDRG?
BERLDRG has an ROE of 6.30%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Beryl Drugs Ltd generates profits from shareholders capital.
How is BERLDRG debt-to-equity ratio and what does it indicate?
BERLDRG has a debt-to-equity ratio of 0.45, which indicates moderate leverage that should be monitored.
What is BERLDRG dividend yield and is it a good dividend stock?
BERLDRG offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Beryl Drugs Ltd shares.
How has BERLDRG share price grown over the past 5 years?
BERLDRG has achieved 5-year growth rates of: Sales Growth 10.60%, Profit Growth 63.26%, and EPS Growth 63.26%.
What is the promoter holding in BERLDRG and why does it matter?
Promoters hold 26.38% of BERLDRG shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Beryl Drugs Ltd.
What is BERLDRG market capitalisation category?
BERLDRG has a market capitalisation of ₹12 crores, placing it in the Small-cap category.
How volatile is BERLDRG stock?
BERLDRG has a beta of N/A. A beta > 1 suggests the Beryl Drugs Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is BERLDRG operating profit margin trend?
BERLDRG has a 5-year average Operating Profit Margin (OPM) of 7.18%, indicating the company's operational efficiency.
How is BERLDRG quarterly performance?
Recent quarterly performance shows Beryl Drugs Ltd YoY Sales Growth of -8.51% and YoY Profit Growth of 0.00%.
What is the institutional holding pattern in BERLDRG?
BERLDRG has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Beryl Drugs Ltd stock.